These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30449217)

  • 1. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
    Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
    Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study.
    Lesén E; Granfeldt D; Houchard A; Berthon A; Dinet J; Gabriel S; Björstad Å; Björholt I; Elf AK; Johanson V
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12983. PubMed ID: 30652364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
    Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
    Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
    Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
    Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
    Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
    Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
    Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
    J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
    Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
    World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
    Kimbrough CW; Beal EW; Dillhoff ME; Schmidt CR; Pawlik TM; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Crown A; Abbott DE; Fisher AV; Fields RC; Krasnick BA; Idrees K; Marincola-Smith P; Cho CS; Beems M; Maithel SK; Cloyd JM
    Surgery; 2019 Mar; 165(3):657-663. PubMed ID: 30377003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.
    Halperin DM; Huynh L; Beaumont JL; Cai B; Bhak RH; Narkhede S; Totev T; Duh MS; Neary MP; Cella D
    BMC Cancer; 2019 Mar; 19(1):274. PubMed ID: 30922252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database.
    Perrier M; Mouawad C; Gueguen D; Thomé B; Lapeyre-Mestre M; Walter T
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102177. PubMed ID: 37453678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center.
    Jalbert JJ; Casciano R; Meng J; Brais LK; Pulgar SJ; Berthon A; Dinet J; Kulke MH
    Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31999024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
    Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
    World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
    Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
    World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
    Pasricha G; Padhi P; Daboul N; Monga DK
    Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report.
    Gerson JN; Witteles RM; Chang DT; Beygui RE; Iagaru AH; Kunz PL
    Pancreas; 2017; 46(10):1381-1385. PubMed ID: 29040196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
    Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
    Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.